Lenvatinib. an oral small-molecule multiple tyrosine kinase inhibitor (TKI). has been approved for first-line therapy for unresectable hepatocellular carcinoma (HCC). Proteinuria is one of the most common adverse events associated with lenvatinib treatment. https://shopredoners.shop/product-category/3-pack-classic-tee/